Clesrovimab Safe for High-Risk Infants Over Two RSV Seasons

The long-acting monoclonal antibody clesrovimab demonstrated good tolerability in infants at high risk for severe respiratory syncytial virus (RSV) disease over two RSV seasons. This finding comes from a randomized clinical trial designed to assess the safety and efficacy of the drug, marketed as Enflonsia, for RSV prevention.

The trial enrolled infants identified as being at increased risk for severe RSV outcomes. These infants received clesrovimab, and their tolerance to the treatment was monitored throughout two full RSV seasons. The study's primary objective was to evaluate the safety profile of the extended treatment regimen, with a focus on adverse events and overall tolerability.

While the provided text snippet does not detail specific adverse events or efficacy data, it emphasizes the positive tolerability observed. This suggests that clesrovimab could be a viable option for prolonged protection against RSV in vulnerable pediatric populations. Further details regarding the trial's methodology, participant numbers, and specific safety outcomes would be necessary to fully understand the implications of these findings for clinical practice and public health recommendations regarding RSV prevention in infants.